X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with SUVEN LIFE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs SUVEN LIFE - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA SUVEN LIFE SANOFI INDIA/
SUVEN LIFE
 
P/E (TTM) x 38.9 20.2 193.0% View Chart
P/BV x 8.4 4.4 190.5% View Chart
Dividend Yield % 1.1 0.5 207.4%  

Financials

 SANOFI INDIA   SUVEN LIFE
EQUITY SHARE DATA
    SANOFI INDIA
Dec-16
SUVEN LIFE
Mar-18
SANOFI INDIA/
SUVEN LIFE
5-Yr Chart
Click to enlarge
High Rs4,560251 1,818.2%   
Low Rs4,400155 2,838.7%   
Sales per share (Unadj.) Rs1,028.549.1 2,093.6%  
Earnings per share (Unadj.) Rs129.09.7 1,327.1%  
Cash flow per share (Unadj.) Rs186.011.4 1,632.5%  
Dividends per share (Unadj.) Rs68.001.50 4,533.3%  
Dividend yield (eoy) %1.50.7 205.3%  
Book value per share (Unadj.) Rs753.660.3 1,249.9%  
Shares outstanding (eoy) m23.03127.28 18.1%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x4.44.1 105.5%   
Avg P/E ratio x34.720.9 166.4%  
P/CF ratio (eoy) x24.117.8 135.2%  
Price / Book Value ratio x5.93.4 176.6%  
Dividend payout %52.715.4 341.6%   
Avg Mkt Cap Rs m103,17425,825 399.5%   
No. of employees `0003.61.1 338.0%   
Total wages/salary Rs m3,592613 586.3%   
Avg. sales/employee Rs Th6,537.75,832.6 112.1%   
Avg. wages/employee Rs Th991.4571.5 173.5%   
Avg. net profit/employee Rs Th819.81,153.8 71.1%   
INCOME DATA
Net Sales Rs m23,6866,253 378.8%  
Other income Rs m708233 304.3%   
Total revenues Rs m24,3946,485 376.1%   
Gross profit Rs m5,2811,982 266.5%  
Depreciation Rs m1,313213 616.1%   
Interest Rs m1546 32.4%   
Profit before tax Rs m4,6611,955 238.4%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m1,691718 235.4%   
Profit after tax Rs m2,9701,237 240.1%  
Gross profit margin %22.331.7 70.3%  
Effective tax rate %36.336.7 98.8%   
Net profit margin %12.519.8 63.4%  
BALANCE SHEET DATA
Current assets Rs m15,6735,622 278.8%   
Current liabilities Rs m6,6781,168 571.9%   
Net working cap to sales %38.071.2 53.3%  
Current ratio x2.34.8 48.7%  
Inventory Days Days7681 93.3%  
Debtors Days Days2236 62.1%  
Net fixed assets Rs m8,0983,325 243.6%   
Share capital Rs m230127 180.9%   
"Free" reserves Rs m17,0887,547 226.4%   
Net worth Rs m17,3567,674 226.2%   
Long term debt Rs m014 0.0%   
Total assets Rs m25,4009,135 278.0%  
Interest coverage x311.743.2 721.2%   
Debt to equity ratio x00 0.0%  
Sales to assets ratio x0.90.7 136.2%   
Return on assets %11.814.0 83.7%  
Return on equity %17.116.1 106.2%  
Return on capital %26.926.0 103.5%  
Exports to sales %24.50-   
Imports to sales %28.00-   
Exports (fob) Rs m5,801NA-   
Imports (cif) Rs m6,627NA-   
Fx inflow Rs m7,1455,066 141.0%   
Fx outflow Rs m6,8462,001 342.1%   
Net fx Rs m2993,065 9.8%   
CASH FLOW
From Operations Rs m3,226699 461.3%  
From Investments Rs m-1,555-6 25,491.8%  
From Financial Activity Rs m-1,818-577 315.1%  
Net Cashflow Rs m-147116 -126.4%  

Share Holding

Indian Promoters % 0.0 63.4 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 0.0 -  
FIIs % 14.6 0.0 -  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 36.5 28.8%  
Shareholders   15,184 37,287 40.7%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   WOCKHARDT LTD.  J.B.CHEMICALS  MERCK LTD  DIVIS LABORATORIES  FULFORD INDIA  

Compare SANOFI INDIA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Sensex Ends 170 Points Lower, Realty and FMCG Stocks Witness Selling(Closing)

After opening the day on a positive note, share markets in India witnessed volatile trading activity and ended in red.

Related Views on News

SUVEN LIFE 2017-18 Annual Report Analysis (Annual Result Update)

Aug 14, 2018 | Updated on Aug 14, 2018

Here's an analysis of the annual report of SUVEN LIFE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of SUVEN LIFE. Also includes updates on the valuation of SUVEN LIFE.

SANOFI INDIA Announces Quarterly Results (1QFY19); Net Profit Up 35.1% (Quarterly Result Update)

Jul 27, 2018 | Updated on Jul 27, 2018

For the quarter ended June 2018, SANOFI INDIA has posted a net profit of Rs 996 m (up 35.1% YoY). Sales on the other hand came in at Rs 7 bn (up 13.8% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

Suven Lifesciences: Profits Decline due to Higher tax outgo in the quarter (Quarterly Results Update - Detailed)

Sep 22, 2017

Muted growth in CRAMS segment continues to impact topline.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

More Views on News

Most Popular

Is It the Right Time to Buy Pharma Stocks Now?(The 5 Minute Wrapup)

Sep 12, 2018

Is the pharma sector poised for a comeback? Is the worst over? I believe so.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

The Secret Of Mirae Asset India Equity Fund's Increasing Popularity(Outside View)

Sep 7, 2018

The prudent investment strategies followed at the fund house has helped Mirae Asset India Equity Fund earn a tag of being a consistent performer, which is in turn gaining popularity among investors.

Should You Be Worried About the Rising Dollar?(Chart Of The Day)

Sep 7, 2018

While the rupee has deprecated by about 5% annually since 1990 against the dollar, the BSE Sensex has returned 14% annually in the same period.

Revenge of the Ratings Agencies(Vivek Kaul's Diary)

Sep 7, 2018

Do you remember when ratings agencies ruled financial markets? Nick explains why he thinks it's time to prepare yourselves for a comeback of the ratings agencies.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Sep 19, 2018 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA - ALEMBIC PHARMA COMPARISON

COMPARE SANOFI INDIA WITH

MARKET STATS